Professor Gavin Halbert

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

I obtained a pharmacy degree from the University of Strathclyde in 1979 followed by a PhD in Physiochemical Aspects of Anti-Cancer Drug Targeting Systems in 1984. I worked during pre-registration in industrial and hospital pharmacy settings, joined SIPBS as a lecturer in 1984 and was appointed Director of the Formulation Unit in 1992. The Unit's role is to characterise, analyse, formulate and manufacture putative anti-cancer drugs accepted by CRUK's New Agents Committee for use in human clinical trials, where I have now been pharmaceutically responsible for over 20 novel NCE's. Arising from this are research interests, which include medicinal and analytical chemistry, drug physiochemistry, formulation for both small volume and parenteral and oral products and the GMP production of specialist pharmaceutical products for phase l clinical trials. The latter incorporates research areas such as microbiology and lyophilisation. In addition related research is conducted in drug targeting and delivery systems for cancer chemotherapy for example the utilisation of synthetic Low Density Lipoprotein systems. I have over £10 million in personal career grant income and over 150 published papers, conference abstracts and presentations.

Undergraduate teaching is limited due to the nature of the Formulation Unit's activities to introductory and specialist courses associated with the areas above applicable to undergraduate pharmacists. Since 1987 I have been involved in post qualification education teaching for the pharmaceutical industry and initiated and teach on the joint SIPBS-David Begg Associates Qualified Persons training course which has been running since 1991.

Publications

Development and implementation of a pneumatic micro-feeder for poorly-flowing solid pharmaceutical materials: Hou P, Besenhard MO, Halbert G, Naftaly M, Markl D; International Journal of Pharmaceutics Vol 635 (2023); https://doi.org/10.1016/j.ijpharm.2023.122691
Acidic drugs - intestinal solubility correlation fasted and fed in vitro vs ex vivo: Halbert Gavin, Inês Silva Maria, Abuhassan Qamar, Khadra Ibrahim, Pyper Kate, Augustijns Patrick, Brouwer Joachim; 4th European Conference on Pharmaceutics (2023)
Fed intestinal solubility limits and distributions applied to the developability classification system: Silva Maria Inês, Khadra Ibrahim, Pyper Kate, Halbert Gavin W; European Journal of Pharmaceutics and Biopharmaceutics Vol 186, pp. 74-84 (2023); https://doi.org/10.1016/j.ejpb.2023.03.005
High spatial resolution ToF-SIMS imaging and image analysis strategies to monitor and quantify early phase separation in amorphous solid dispersions: Paladino Eleonora, Doerr Frederik JS, Bordos Ecaterina, Onyemelukwe Iyke I, Lamprou Dimitrios A, Florence Alastair J, Gilmore Ian S, Halbert Gavin W; International Journal of Pharmaceutics Vol 628 (2022); https://doi.org/10.1016/j.ijpharm.2022.122191
Solubility measurement of poorly soluble drugs in fasted state simulated intestinal fluid: McKinnon Zoe, Batchelor Hannah, Khadra Ibrahim, Halbert Gavin; British Journal of Pharmacy Vol 7 (2022); https://doi.org/10.5920/bjpharm.1075
Identifying the operating space and repeatability of a novel filament free FDM printer: Prasad Elke, Robertson John, Halbert Gavin W; AAPS 2022 Pharm Sci 360 (2022)

More publications

Professional activities

Opening up the pharmaceutical formulation space for Additive Manufacturing: Contributor; 6/10/2021
ToF-SIMS imaging of amorphous solid dispersions: a stability study: Contributor; 23/10/2019
3D imaging of controlled-release electrospun material: Contributor; 12/9/2017
ToF-SIMS imaging of pharmaceutical samples: case-studies: Contributor; 30/11/2016
Cencer Research UK (External organisation): Member; 2011
Invited talk at BPC September 2009: Invited speaker; 2009

More professional activities

Projects

KTP - Target Healthcare Limited. Development of platform capability and creation of a robust framework for the assessment of shelf life and stability of a range of aseptically prepared Monoclonal Anti-Bodies (MABs) for patient use.: Perrie, Yvonne (Principal Investigator) Halbert, Gavin (Co-investigator); 24-Jan-2022 - 23-Jan-2024
Royal Society of Chemistry: Developing an analytical toolbox for modelling antibody aggregation: Rattray, Zahra (Principal Investigator) Halbert, Gavin (Principal Investigator) Considine, Paul (Researcher); Summer internship funded by Royal Society of Chemistry- £2600; 13-Jan-2022 - 12-Jan-2022
Doctoral Training Partnership 2020-2021 University of Strathclyde | Ugorenko, Agata: Perrie, Yvonne (Principal Investigator) Halbert, Gavin (Co-investigator) Ugorenko, Agata (Research Co-investigator); 01-Jan-2021 - 01-Jan-2025
Multiscale Metrology Suite for Next-generation Healthcare Technologies (EPSRC Strategic Equipment): Rattray, Zahra (Principal Investigator) Bruns, Nico (Co-investigator) Faulds, Karen (Co-investigator) Graham, Duncan (Co-investigator) Halbert, Gavin (Co-investigator) Hoskins, Clare (Co-investigator) McArthur, Stephen (Co-investigator) Perrie, Yvonne (Co-investigator) Reid, Stuart (Co-investigator) Seib, Philipp (Co-investigator); 01-Jan-2021 - 31-Jan-2024
Cancer Research UK Formulation Unit for the pharmaceutical and bio-pharmaceutical evaluation of new anti-cancer drugs C149/A28424: Halbert, Gavin (Principal Investigator) Cygan Barlow, Paulina (Co-investigator) Dick, Lindsay (Co-investigator) Elliott, Moira (Co-investigator); Cancer Research UK Formulation Unit Quinquennial Proposal year 1; 01-Jan-2020 - 30-Jan-2023
Covid Vaccine Project: Halbert, Gavin (Principal Investigator) Dick, Lindsay (Co-investigator) Irvine, Christopher (Co-investigator); 01-Jan-2020 - 05-Jan-2023

More projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Robertson Wing

Location Map

View University of Strathclyde in a larger map